NCT04954339 (DYNAMIC) is a Phase 2 clinical trial of Aatezolizumab plus Bevacizumab in Hepatocellular Carcinoma, sponsored by Tae Won Kim.

Who is sponsoring NCT04954339?

NCT04954339 is sponsored by Tae Won Kim.

What drugs are being tested in NCT04954339?

Interventions in NCT04954339: Aatezolizumab plus Bevacizumab.

What condition does NCT04954339 study?

NCT04954339 studies Hepatocellular Carcinoma.

Is NCT04954339 still recruiting?

NCT04954339 is currently active, enrolled. Last updated 31 May 2025.

Last reviewed 2025-05-31 · How we verify

NCT04954339: DYNAMIC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab

Active, enrolled Phase 2 Last updated 31 May 2025

What this trial tests

Phase 2 trial testing Aatezolizumab plus Bevacizumab in Hepatocellular Carcinoma in 40 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

29 October 2021

Primary endpoint
30 June 2026

31 December 2026

Quick facts

Lead sponsor	Tae Won Kim
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	29 October 2021
Primary completion	30 June 2026
Estimated completion	31 December 2026
Sites	1 location across South Korea

Drugs / interventions tested

Aatezolizumab plus Bevacizumab — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

Tae Won Kim — full company profile →

Who can join

19 and older, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Part I (Clinical trial setting): A single-arm phase II study to investigate the efficacy of neoadjuvant atezolizumab (T) + bevacizumab (A) in patients with potentially resectable BCLC stage B/C or high risk resectable hepatocellular carcinoma (HCC) (n = 45) Part II (Biomarker study setting): Exploratory translational research will be conducted using samples obtained from Part 1 (n =45) and those acquired from an independent cohort of treatment-naïve HCC patients (n = 15).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Neoadjuvant Therapy for Hepatocellular Carcinoma.
Yin Z, Chen D, Liang S, Li X. · · 2022 · cited 22× · PMID 36068876 · DOI 10.2147/jhc.s357313
Neoadjuvant Immunotherapy for Hepatocellular Carcinoma.
Marron TU, Schwartz M, Corbett V, Merad M. · · 2022 · cited 19× · PMID 35794901 · DOI 10.2147/jhc.s340935
Systemic Neoadjuvant and Adjuvant Therapies in the Management of Hepatocellular Carcinoma-A Narrative Review.
Chamseddine S, LaPelusa M, Kaseb AO. · · 2023 · cited 17× · PMID 37444618 · DOI 10.3390/cancers15133508
Neoadjuvant systemic therapy for hepatocellular carcinoma.
Chick RC, Ruff SM, Pawlik TM. · · 2024 · cited 16× · PMID 38495884 · DOI 10.3389/fimmu.2024.1355812
Preoperative Immunotherapy in Hepatocellular Carcinoma: Current State of the Art.
Laschtowitz A, Roderburg C, Tacke F, Mohr R. · · 2023 · cited 13× · PMID 36789252 · DOI 10.2147/jhc.s347944
Next-Generation Immunotherapy for Hepatocellular Carcinoma: Mechanisms of Resistance and Novel Treatment Approaches.
Eghbali S, Heumann TR. · · 2025 · cited 11× · PMID 39858016 · DOI 10.3390/cancers17020236
Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma.
Urquijo-Ponce JJ, Alventosa-Mateu C, Latorre-Sánchez M, Castelló-Miralles I, et al · · 2024 · cited 10× · PMID 38817666 · DOI 10.3748/wjg.v30.i19.2512
Liver resection and transplantation in the era of checkpoint inhibitors.
Tabrizian P, Marino R, Chow PKH. · · 2024 · cited 7× · PMID 39741696 · DOI 10.1016/j.jhepr.2024.101181

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Tae Won Kim trials

Trials by the same sponsor.

NCT04696848 — The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors · Phase 1, PHASE2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04954339 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tae Won Kim
Last refreshed: 31 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04954339.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing